VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 61 filers reported holding VAXCYTE INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 2.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $8,050,197 | +651.5% | 106,611 | +579.8% | 0.00% | – |
| Q1 2024 | $1,071,237 | -75.6% | 15,682 | -77.6% | 0.00% | -100.0% |
| Q4 2023 | $4,391,478 | +20.9% | 69,928 | -3.9% | 0.00% | 0.0% |
| Q2 2023 | $3,632,286 | +389.1% | 72,733 | +267.1% | 0.00% | – |
| Q1 2023 | $742,629 | +92.1% | 19,814 | +145.8% | 0.00% | – |
| Q4 2022 | $386,525 | -2.4% | 8,061 | +0.4% | 0.00% | – |
| Q3 2020 | $396,000 | -6.4% | 8,028 | -40.0% | 0.00% | – |
| Q2 2020 | $423,000 | – | 13,380 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $59,882,148 | 46.04% |
| Darwin Global Management, Ltd. | 2,080,946 | $163,916,116 | 19.07% |
| RA Capital Management | 8,203,754 | $619,465,465 | 8.19% |
| ACUTA CAPITAL PARTNERS, LLC | 110,400 | $8,336,304 | 7.02% |
| COMMODORE CAPITAL LP | 1,305,000 | $98,540,550 | 6.73% |
| Saturn V Capital Management LP | 215,680 | $16,285,997 | 6.15% |
| Cormorant Asset Management, LP | 1,100,000 | $83,061,000 | 4.80% |
| Kynam Capital Management, LP | 753,240 | $56,877,152 | 4.39% |
| Novo Holdings A/S | 950,000 | $71,734,500 | 4.16% |
| Frazier Life Sciences Management, L.P. | 1,039,405 | $78,485,472 | 3.67% |